Cargando…

Association of the TNF-α-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects

OBJECTIVE: An association of the C-857T polymorphism of the tumor necrosis factor-α (TNF-α) gene promoter region with LDL cholesterol levels has been reported. This study was designed to evaluate the relationship between the TNF-α-C-857T polymorphism and LDL cholesterol levels according to statin tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Toru, Takahashi, Kazuma, Yamashina, Mitsuhiro, Maesawa, Chihaya, Kajiwara, Takashi, Taneichi, Haruhito, Takebe, Noriko, Kaneko, Yoshihito, Masuda, Tomoyuki, Satoh, Jo
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827489/
https://www.ncbi.nlm.nih.gov/pubmed/20007938
http://dx.doi.org/10.2337/dc09-1724
_version_ 1782177949273817088
author Takahashi, Toru
Takahashi, Kazuma
Yamashina, Mitsuhiro
Maesawa, Chihaya
Kajiwara, Takashi
Taneichi, Haruhito
Takebe, Noriko
Kaneko, Yoshihito
Masuda, Tomoyuki
Satoh, Jo
author_facet Takahashi, Toru
Takahashi, Kazuma
Yamashina, Mitsuhiro
Maesawa, Chihaya
Kajiwara, Takashi
Taneichi, Haruhito
Takebe, Noriko
Kaneko, Yoshihito
Masuda, Tomoyuki
Satoh, Jo
author_sort Takahashi, Toru
collection PubMed
description OBJECTIVE: An association of the C-857T polymorphism of the tumor necrosis factor-α (TNF-α) gene promoter region with LDL cholesterol levels has been reported. This study was designed to evaluate the relationship between the TNF-α-C-857T polymorphism and LDL cholesterol levels according to statin treatment in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: DNA was obtained from 322 Japanese subjects (160 male and 162 female) with type 2 diabetes, and TNF-α-C-857T polymorphisms were determined by direct sequencing. Serum LDL cholesterol was measured by a direct method. RESULTS: Although serum LDL cholesterol levels were significantly higher in the T carriers (C/T + T/T) than in the non–T carriers (C/C) (3.14 ± 0.86 vs. 2.89 ± 0.75 mmol/l, P < 0.05), there was no difference in LDL cholesterol levels between the non–T carriers and the T carriers in statin-untreated subjects (2.87 ± 0.73 vs. 2.89 ± 0.76 mmol/l, NS), whereas in statin-treated subjects, LDL cholesterol levels were significantly higher in the T carriers than in the non–T carriers (3.43 ± 0.89 vs. 2.90 ± 0.78 mmol/l, P = 0.0007). There were no differences in HDL cholesterol and triglyceride levels between the non–T carriers and the T carriers in both statin-treated and -untreated subjects. The percent decrease in LDL cholesterol levels after administration of statins was significantly smaller in the T carriers compared with the non–T carriers (27.6 vs. 36.4%, P = 0.031). CONCLUSIONS: The mutant allele of the C-857T promoter polymorphism of the TNF-α gene may predispose to resistance to the LDL cholesterol–lowering effect of statins and could be one of the markers used to predict the efficacy of statins.
format Text
id pubmed-2827489
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-28274892011-03-01 Association of the TNF-α-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects Takahashi, Toru Takahashi, Kazuma Yamashina, Mitsuhiro Maesawa, Chihaya Kajiwara, Takashi Taneichi, Haruhito Takebe, Noriko Kaneko, Yoshihito Masuda, Tomoyuki Satoh, Jo Diabetes Care Original Research OBJECTIVE: An association of the C-857T polymorphism of the tumor necrosis factor-α (TNF-α) gene promoter region with LDL cholesterol levels has been reported. This study was designed to evaluate the relationship between the TNF-α-C-857T polymorphism and LDL cholesterol levels according to statin treatment in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: DNA was obtained from 322 Japanese subjects (160 male and 162 female) with type 2 diabetes, and TNF-α-C-857T polymorphisms were determined by direct sequencing. Serum LDL cholesterol was measured by a direct method. RESULTS: Although serum LDL cholesterol levels were significantly higher in the T carriers (C/T + T/T) than in the non–T carriers (C/C) (3.14 ± 0.86 vs. 2.89 ± 0.75 mmol/l, P < 0.05), there was no difference in LDL cholesterol levels between the non–T carriers and the T carriers in statin-untreated subjects (2.87 ± 0.73 vs. 2.89 ± 0.76 mmol/l, NS), whereas in statin-treated subjects, LDL cholesterol levels were significantly higher in the T carriers than in the non–T carriers (3.43 ± 0.89 vs. 2.90 ± 0.78 mmol/l, P = 0.0007). There were no differences in HDL cholesterol and triglyceride levels between the non–T carriers and the T carriers in both statin-treated and -untreated subjects. The percent decrease in LDL cholesterol levels after administration of statins was significantly smaller in the T carriers compared with the non–T carriers (27.6 vs. 36.4%, P = 0.031). CONCLUSIONS: The mutant allele of the C-857T promoter polymorphism of the TNF-α gene may predispose to resistance to the LDL cholesterol–lowering effect of statins and could be one of the markers used to predict the efficacy of statins. American Diabetes Association 2010-03 2009-12-10 /pmc/articles/PMC2827489/ /pubmed/20007938 http://dx.doi.org/10.2337/dc09-1724 Text en © 2010 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details.
spellingShingle Original Research
Takahashi, Toru
Takahashi, Kazuma
Yamashina, Mitsuhiro
Maesawa, Chihaya
Kajiwara, Takashi
Taneichi, Haruhito
Takebe, Noriko
Kaneko, Yoshihito
Masuda, Tomoyuki
Satoh, Jo
Association of the TNF-α-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects
title Association of the TNF-α-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects
title_full Association of the TNF-α-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects
title_fullStr Association of the TNF-α-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects
title_full_unstemmed Association of the TNF-α-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects
title_short Association of the TNF-α-C-857T Polymorphism With Resistance to the Cholesterol-Lowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects
title_sort association of the tnf-α-c-857t polymorphism with resistance to the cholesterol-lowering effect of hmg-coa reductase inhibitors in type 2 diabetic subjects
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827489/
https://www.ncbi.nlm.nih.gov/pubmed/20007938
http://dx.doi.org/10.2337/dc09-1724
work_keys_str_mv AT takahashitoru associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT takahashikazuma associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT yamashinamitsuhiro associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT maesawachihaya associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT kajiwaratakashi associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT taneichiharuhito associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT takebenoriko associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT kanekoyoshihito associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT masudatomoyuki associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects
AT satohjo associationofthetnfac857tpolymorphismwithresistancetothecholesterolloweringeffectofhmgcoareductaseinhibitorsintype2diabeticsubjects